Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials
| Autor: | Eugene Gusev, Stefan Winter, Johannes C. Vester, Alla Guekht, Wolf-Dieter Heiss, Dafin F. Muresanu, Volker W. Rahlfs, Herbert Moessler, Edith Doppler, Volker Hoemberg, Ovidiu Bajenaru, Bogdan Ovidiu Popescu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Neurology medicine.medical_treatment Dermatology Motor Activity Placebo 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Recovery Statistical significance medicine Humans 030212 general & internal medicine Amino Acids Stroke Randomized Controlled Trials as Topic Rehabilitation Cerebrolysin Stroke Rehabilitation General Medicine Recovery of Function medicine.disease Psychiatry and Mental health Meta-analysis Neuroprotective Agents chemistry Relative risk Physical therapy Original Article Neurology (clinical) Early benefit Psychology 030217 neurology & neurosurgery NIHSS |
| Zdroj: | Neurological Sciences |
| ISSN: | 1590-3478 1590-1874 |
| Popis: | This meta-analysis combines the results of two identical stroke studies (CARS-1 and CARS-2) assessing efficacy of Cerebrolysin on motor recovery during early rehabilitation. Cerebrolysin is a parenterally administered neuropeptide preparation approved for the treatment of stroke. Both studies had a prospective, randomized, double-blind, placebo-controlled design. Treatment with 30 ml Cerebrolysin once daily for 3 weeks was started 24–72 h after stroke onset. In addition, patients participated in a standardized rehabilitation program for 21 days that was initiated within 72 h after stroke onset. For both studies, the original analysis data were used for meta-analysis (individual patient data analysis). The combination of these two studies by meta-analytic procedures was pre-planned, and the methods were pre-defined under blinded conditions. The nonparametric Mann-Whitney (MW) effect size of the two studies on the ARAT score on day 90 indicated superiority of Cerebrolysin compared with placebo (MW 0.62, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|